IMA: Olevaprubart's phase IIb trial targets high efficacy and safety in atopic dermatitis, with key data due next year
Olevaprubart, a next-generation OX40 antibody, is in phase IIb trials for atopic dermatitis and alopecia areata, aiming for superior efficacy and safety over prior OX40 programs. Top-line phase IIb data is expected in Q4 next year, with strong financial runway and new PK data to be presented at EAD…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.